Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HaleonHAM:H6D +0.63%73 EV-to-OCF is 16.28 as of Sep. 22, 2026, which is 14% below its 10-year median of 18.89. GuruFocus rates HAM:H6D with a GF Score™ of 73/100 and a GF Value™ of €8.59. The stock has 2 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Haleon ranks worse than 59.84% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Haleon's Enterprise Value is €43,664 Mil.
Haleon's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €2,683 Mil. Therefore, Haleon's EV-to-OCF for today is 16.28.
The historical rank and industry rank for Haleon's EV-to-OCF or its related term are showing as below:
HAM:H6D'
s EV-to-OCF Range Over the Past 10 Years
Min: 13.89 Med: 18.89 Max: 22.86
Current: 13.89
During the past 7 years, the highest EV-to-OCF of Haleon was 22.86. The lowest was 13.89. And the median was 18.89.
HAM:H6D's EV-to-OCF is ranked worse than 59.84% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.21
vs HAM:H6D: 13.89
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-09-22), Haleon's stock price is €8.00.
Haleon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.417. Therefore, Haleon's PE Ratio (TTM) for today is 19.18.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Haleon's share price for today is €8.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haleon's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.417.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Haleon EV-to-OCF Related Terms
Haleon EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Haleon's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Haleon's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleon EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Haleon's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Haleon's EV-to-OCF falls into.
Haleon's current Enterprise Value is €43,664 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Haleon's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €2,683 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleon (HAM:H6D) has a EV-to-OCF of 16.28 as of Sep. 22, 2026. This is 14% below median its historical median of 18.89. Over the past decade, Haleon's EV-to-OCF has ranged from 13.89 to 22.86. According to the industry distribution chart, Haleon ranks #602 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 59.8%.
Is Haleon's EV-to-OCF too high?
Haleon's current EV-to-OCF of 16.28 is 14% below median its 10-year median of 18.89. Over the past 10 years, this metric has ranged from a low of 13.89 to a high of 22.86. The Drug Manufacturers industry median EV-to-OCF is 10.21. Haleon's value of 16.28 is 59.5% above this industry median. Based on the distribution chart, Haleon ranks #602 out of 1006 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Haleon has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Haleon's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Haleon ranks #602 out of 1006 companies for EV-to-OCF. This places Haleon in the lower half of its industry. The industry median EV-to-OCF is 10.21. Haleon's value of 16.28 is 59.5% above this benchmark. Historically, Haleon's own EV-to-OCF has ranged from 13.89 to 22.86 over the past decade. While the company's 10-year median is 18.89 vs. the industry median of 10.21, Haleon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.21, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleon's current EV-to-OCF of 16.28 is 59.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleon's current EV-to-OCF is 16.28, which is 14% below median its own 10-year median of 18.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleon stock overvalued right now?
Haleon (HAM:H6D) has a current EV-to-OCF of 16.28. The stock's GF Value™ is €8.59, compared to a current price of €8.00 — trading 6.9% below its estimated fair value. The current EV-to-OCF is 16.28, which is 14% below median its 10-year median of 18.89 and 59.5% above the Drug Manufacturers industry median of 10.21. Haleon's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Haleon (HAM:H6D), the current EV-to-OCF is 16.28 as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleon (HAM:H6D) Overvalued in 2026?
Based on GuruFocus' analysis, Haleon stock appears to be undervalued.
The current stock price of €8.00 is trading 6.9% below its estimated GF Value™ of €8.59.
Key valuation signals for HAM:H6D:
EV-to-OCF: 16.28 (14% below median its 10-year median of 18.89)
GF Value™: €8.59 vs. price of €8.00 (6.9% below fair value)
Industry Position: 59.5% above the Drug Manufacturers median (#602 of 1006)
No single metric tells the full story. See the HAM:H6D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon's brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
73GF Score
Get the complete analysis for HAM:H6D
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:H6D has been successfully added to your 
